Dawnrays Pharmaceutical Holdings
Dawnrays Pharmaceutical Holdings Limited, commonly referred to as Dawnrays, is a prominent player in the pharmaceutical industry, headquartered in Hong Kong (HK). Established in 1992, the company has made significant strides in the development, manufacturing, and marketing of a diverse range of pharmaceutical products, particularly in the fields of anti-infectives, oncology, and cardiovascular treatments. With a strong operational presence across Asia and beyond, Dawnrays is recognised for its commitment to quality and innovation. The company’s core offerings include generic and proprietary drugs, which are distinguished by their efficacy and affordability. Notably, Dawnrays has achieved several milestones, including regulatory approvals and partnerships that enhance its market position. As a result, it has established itself as a trusted name in the pharmaceutical sector, dedicated to improving global health outcomes.
DitchCarbon Score
How does Dawnrays Pharmaceutical Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dawnrays Pharmaceutical Holdings's score of 2 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Dawnrays Pharmaceutical Holdings's reported carbon emissions
In 2023, Dawnrays Pharmaceutical Holdings, headquartered in Hong Kong, reported total carbon emissions of approximately 42,079,000 kg CO2e. This figure includes about 4,529,000 kg CO2e from Scope 1 emissions and approximately 37,557,000 kg CO2e from Scope 2 emissions. Comparatively, the company's emissions have fluctuated over recent years, with 2022 emissions at about 27,864,000 kg CO2e, 2021 at approximately 26,771,000 kg CO2e, and 2020 at around 35,903,000 kg CO2e. Notably, the increase in emissions from 2022 to 2023 indicates a significant rise in their carbon footprint. Dawnrays has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon emissions. The absence of climate pledges or commitments suggests that the company may be in the early stages of developing a comprehensive climate strategy. As the pharmaceutical industry increasingly faces scrutiny regarding environmental impact, it will be essential for Dawnrays to establish clear climate commitments to align with global sustainability goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 666,000 | 000,000 | 000,000 | 0,000,000 |
| Scope 2 | 35,237,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dawnrays Pharmaceutical Holdings is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
